RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Clinician perspectives of gene therapy as a treatment option for Duchenne muscular dystrophy
Cope, H., Fischer, R., Heslop, E., McNiff, M., Johnson, A., Camino, E., Denger, B., Armstrong, N., Thakrar, S., Bateman-House, A., Beaverson, K. L., Woollacott, I. O. C., Phillips, D., Fernandez, V., Ganot, A., Donisa-Dreghici, R., Mansfield, C., & Peay, H. (2024). Clinician perspectives of gene therapy as a treatment option for Duchenne muscular dystrophy. Journal of Neuromuscular Diseases, (5), 1-9. https://doi.org/10.3233/JND-240033
BACKGROUND: Duchenne muscular dystrophy (DMD) is a progressive, life-limiting, neuromuscular disorder. Clinicians play an important role in informing families about therapy options, including approved gene therapies and clinical trials of unapproved therapies.
OBJECTIVE: This study aimed to understand the perspectives of clinicians about gene therapy for DMD, which has not previously been studied.
METHODS: We conducted interviews with specialist clinicians treating patients with DMD in the United States (n = 8) and United Kingdom (n = 8). Interviews were completed in 2022, before any approved gene therapies, to gain insight into barriers and facilitators to implementing gene therapy and educational needs of clinicians.
RESULTS: Most respondents expressed cautious optimism about gene therapy. Responses varied regarding potential benefits with most expecting delayed progression and duration of benefit (1 year to lifelong). Concern about anticipated risks also varied; types of anticipated risks included immunological reactions, liver toxicity, and cardiac or renal dysfunction. Clinicians generally, but not uniformly, understood that gene therapy for DMD would not be curative. Most reported needing demonstrable clinical benefit to justify treatment-related risks.
CONCLUSIONS: Our data demonstrate variability in knowledge and attitudes about gene therapy among clinicians who follow patients with DMD. As our knowledge base about DMD gene therapy grows, clinician education is vital to ensuring that accurate information is communicated to patients and families.
